AU2009345773A1 - Paeoniflorin preparations and uses thereof for fat reduction - Google Patents

Paeoniflorin preparations and uses thereof for fat reduction Download PDF

Info

Publication number
AU2009345773A1
AU2009345773A1 AU2009345773A AU2009345773A AU2009345773A1 AU 2009345773 A1 AU2009345773 A1 AU 2009345773A1 AU 2009345773 A AU2009345773 A AU 2009345773A AU 2009345773 A AU2009345773 A AU 2009345773A AU 2009345773 A1 AU2009345773 A1 AU 2009345773A1
Authority
AU
Australia
Prior art keywords
preparation
adipolysis
fat
paeoniflorin
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009345773A
Other languages
English (en)
Inventor
Bakr Rabie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2009345773A1 publication Critical patent/AU2009345773A1/en
Assigned to RABIE, BAKR reassignment RABIE, BAKR Request for Assignment Assignors: PROFOUND ASIA TECHNOLOGY LTD.
Priority to AU2015242976A priority Critical patent/AU2015242976A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0452—Specially adapted for transcutaneous muscle stimulation [TMS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N2007/0004—Applications of ultrasound therapy
    • A61N2007/0008—Destruction of fat cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Electrotherapy Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AU2009345773A 2008-05-23 2009-05-25 Paeoniflorin preparations and uses thereof for fat reduction Abandoned AU2009345773A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015242976A AU2015242976A1 (en) 2008-05-23 2015-10-13 Paeoniflorin preparations and uses thereof for fat reduction

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/126,246 US7943187B2 (en) 2008-05-23 2008-05-23 Paeoniflorin preparations and uses thereof for fat reduction
US12/126,246 2008-05-23
PCT/CN2009/000569 WO2010127470A1 (en) 2008-05-23 2009-05-25 Paeoniflorin preparations and uses thereof for fat reduction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015242976A Division AU2015242976A1 (en) 2008-05-23 2015-10-13 Paeoniflorin preparations and uses thereof for fat reduction

Publications (1)

Publication Number Publication Date
AU2009345773A1 true AU2009345773A1 (en) 2010-11-11

Family

ID=41342622

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2009345773A Abandoned AU2009345773A1 (en) 2008-05-23 2009-05-25 Paeoniflorin preparations and uses thereof for fat reduction
AU2015242976A Abandoned AU2015242976A1 (en) 2008-05-23 2015-10-13 Paeoniflorin preparations and uses thereof for fat reduction

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2015242976A Abandoned AU2015242976A1 (en) 2008-05-23 2015-10-13 Paeoniflorin preparations and uses thereof for fat reduction

Country Status (9)

Country Link
US (4) US7943187B2 (OSRAM)
EP (1) EP2300018B1 (OSRAM)
JP (1) JP5507549B2 (OSRAM)
KR (1) KR101656536B1 (OSRAM)
CN (1) CN102170888B (OSRAM)
AU (2) AU2009345773A1 (OSRAM)
CA (1) CA2725972A1 (OSRAM)
DK (1) DK2300018T3 (OSRAM)
WO (1) WO2010127470A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943187B2 (en) * 2008-05-23 2011-05-17 Bakr Rabie Paeoniflorin preparations and uses thereof for fat reduction
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20130012840A1 (en) * 2010-03-23 2013-01-10 Real Aesthetics Ltd. System and method for accelerating the relative proportion of fat catabolism
CA2827643C (en) 2011-02-18 2019-05-07 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
WO2015061280A1 (en) 2013-10-21 2015-04-30 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
WO2017079700A1 (en) * 2015-11-04 2017-05-11 Kythera Biopharmaceuticals, Inc. Treatments of accumulated fat with deoxycholic acid and salts thereof
WO2019156213A1 (ja) 2018-02-09 2019-08-15 琥珀バイオテクノロジー株式会社 グリセロール放出促進剤
KR102392292B1 (ko) 2021-07-21 2022-05-03 중앙대학교 산학협력단 페오니플로린을 포함하는 악액질 및 근손실 예방 또는 치료용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6485990A (en) * 1987-09-28 1989-03-30 Tsumura & Co Antihypertestoeronemia agent
US4888354A (en) * 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
US5919621A (en) 1991-10-24 1999-07-06 Brown; David B. Methods for diagnosing human male infertility
IL101387A (en) * 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US5480772A (en) 1993-02-03 1996-01-02 Brandeis University In vitro activation of a nucleus
FR2717382B1 (fr) * 1994-03-21 1996-06-07 Fabre Pierre Cosmetique Extraits de Paeonia Lactiflora titré en paeoniflorine utiles en cosmétologie dans le traitement capillaire.
PE17897A1 (es) * 1995-02-17 1997-06-12 Lilly Co Eli Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano
US5698199A (en) * 1995-03-10 1997-12-16 Kao Corporation Lipolysis acceleration method
EP1021191B1 (de) 1997-10-08 2002-06-05 Genesiscosmetics Rights & Licenses Company Limited Straffung und/oder verkleinerung von fettzellen-haltigen körperpartien
US6638064B1 (en) * 2000-06-07 2003-10-28 Robert Scott Nance Flexible endodontic syringe
ES2333849T3 (es) * 2001-04-20 2010-03-02 Alza Corporation Disposicion de microsalientes que presenta un revestimiento que contiene un agente beneficioso.
CN2560367Y (zh) * 2001-08-30 2003-07-16 夏勤 适于喉部和气管滴入药物的针头
US20030175328A1 (en) * 2002-03-06 2003-09-18 Adi Shefer Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin
JP2004217583A (ja) * 2003-01-16 2004-08-05 Naris Cosmetics Co Ltd 痩身用皮膚外用剤
US20040191330A1 (en) * 2003-03-31 2004-09-30 Keefe Candace R. Daily skin care regimen
CN1555806A (zh) * 2003-12-31 2004-12-22 昆明同持医药研究有限公司 一种芍药甙注射剂及其制备方法和应用
US20080194496A1 (en) * 2004-05-10 2008-08-14 Lg Household & Health Care Ltd. Skin Aging Treatment Comprising Paeoniflorin
KR100769580B1 (ko) * 2005-03-07 2007-10-23 주식회사 엘지생활건강 자외선에 의한 피부 ｄｎａ 손상 방지제
KR20050107649A (ko) * 2004-05-10 2005-11-15 주식회사 엘지생활건강 페오니플로린을 포함하는 피부 노화 억제용 조성물
ES2372499T3 (es) 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
US7530958B2 (en) * 2004-09-24 2009-05-12 Guided Therapy Systems, Inc. Method and system for combined ultrasound treatment
JP4974533B2 (ja) * 2006-01-30 2012-07-11 富士フイルム株式会社 ジスルフィド架橋したタンパク質ナノ粒子
US20080294072A1 (en) * 2007-05-24 2008-11-27 Crutchfield Dermatology Mesotherapy with ultrasound
US7943187B2 (en) * 2008-05-23 2011-05-17 Bakr Rabie Paeoniflorin preparations and uses thereof for fat reduction

Also Published As

Publication number Publication date
US20150018906A1 (en) 2015-01-15
CN102170888A (zh) 2011-08-31
US20090292238A1 (en) 2009-11-26
US20170368086A9 (en) 2017-12-28
KR20110138322A (ko) 2011-12-27
WO2010127470A1 (en) 2010-11-11
EP2300018B1 (en) 2017-05-17
EP2300018A1 (en) 2011-03-30
CN102170888B (zh) 2013-06-19
DK2300018T3 (en) 2017-09-11
US20110218163A1 (en) 2011-09-08
AU2015242976A1 (en) 2015-11-05
KR101656536B1 (ko) 2016-09-12
US8491947B2 (en) 2013-07-23
JP5507549B2 (ja) 2014-05-28
CA2725972A1 (en) 2010-11-11
US9901591B2 (en) 2018-02-27
JP2011523950A (ja) 2011-08-25
US20170216333A1 (en) 2017-08-03
US7943187B2 (en) 2011-05-17
EP2300018A4 (en) 2011-07-20
HK1159477A1 (en) 2012-08-03

Similar Documents

Publication Publication Date Title
US9901591B2 (en) Paeoniflorin preparations and uses thereof for fat reduction
KR20200054171A (ko) 경피 칸나비디올 겔을 이용한 골관절염의 치료 방법
US11382513B2 (en) Methods and compositions for treating a condition in a subject
Abbasi et al. Iontophoresis and electroporation-assisted microneedles: advancements and therapeutic potentials in transdermal drug delivery
KR101935219B1 (ko) 국소 지방 및 체중 감소용 조성물 및 그의 제약 및 용도
WO2016201286A1 (en) Treatment of sexual dysfunction
JP2018516934A (ja) 脂肪量を低減するためのβ−ヒドロキシ−β−メチルブチレート（ＨＭＢ）の組成物および使用方法
CA2923064A1 (en) Transdermal composition for treating pain
Matarasso et al. Mesotherapy and injection lipolysis
Liao et al. Evaluation of ultrasound combined with chitosan for the control of weight and local fat in mice
CN102580087B (zh) 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法
Chen et al. Low-intensity pulsed ultrasound and parathyroid hormone improve muscle atrophy in estrogen deficiency mice
Barbosa et al. Body harmonization: The definition of a new concept
HK1159477B (en) Paeoniflorin preparations and uses thereof for fat reduction
Upadhyaya et al. Role of an indigenous drug Geriforte on blood levels of biogenic amines and its significance in the treatment of anxiety neurosis
CN113181174A (zh) Bl-1249在制备治疗神经病理性疼痛的药物中的应用
US20070042998A1 (en) Medical cosmetic method for reducing adipose tissue and for initiating lipolysis through subcutaneous and intracutaneous injections and customized composition compounded from pharmaceutical agents for use therein
Abbasi et al. Transdermal delivery of metformin using microneedle and iontophoresis for combating obesity
BERBECE et al. Use of Phosphatidylcholine in the Treatment of Localized Fat Deposits
Braun Lipodissolve for body sculpting
Raffa Analgesic patent applications: I
CN119564656A (zh) 抗炎物质及其应用
Stob Post exercise protein feeding does not alter molecular markers of translation initiation or measures of skeletal muscle function
Beilin Body mesotherapy and ‘mesobotox’
Parada et al. Is dopamine (DA) in the lateral hypothalamus (LH) involved in the inhibitory regulation of exploratory behavior related to food and water seeking?

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RABIE, BAKR

Free format text: FORMER APPLICANT(S): PROFOUND ASIA TECHNOLOGY LTD.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted